Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
Optimi Health’s psychedelic ambitions get a Nasdaq passport as a $15 million oversubscribed offering fuels US expansion bets.
On May 20, 2026, Optimi Health priced an underwritten public offering of 2,400,000 common shares at US$6.25 each, for expected gross proceeds of approximately US$15 million. The offering, led by sole book-running manager Joseph Gunnar & Co., is oversubscribed and conducted in connection with the company’s uplisting to the Nasdaq Capital Market under the symbol “OPTH.” The company completed a 1-for-30 reverse share consolidation on May 19, reducing the outstanding share count to roughly 3,225,881. Proceeds are earmarked for scaling production and distribution in current markets, expansion into the United States, sales growth, and working capital. The underwriter has a 360,000-share over-allotment option and closing is expected on or about May 21, 2026.
The Nasdaq uplisting and concurrent US$15 million raise are significant milestones for Optimi. The oversubscribed status signals institutional demand, and the offering—though dilutive (~43% new shares on the post-consolidation base)—provides critical capital to extend the company’s bridge from Australian early revenues to a potential US market entry. The pricing at a discount to the theoretical post-split price ($6.25 vs. $9.60 based on the pre-split $0.32 close) is standard for such transactions and does not detract from the strategic uplift. However, the event caps a process announced in March 2026, so it is not a complete surprise; the market had already priced in a pending Nasdaq listing. Still, the successful closing and oversubscription elevate the company’s profile and liquidity. The news is material positive but falls short of a game changer given the absence of a first‑time strategic investor block or an outright takeover.
Optimi Health is a Canadian, Health Canada‑licensed GMP manufacturer of pharmaceutical‑grade psychedelic medicines. Operating two 10,000-square-foot facilities in British Columbia, the company produces MDMA and psilocybin capsules for regulated therapeutic use. Its flagship initiative is the supply of these drugs to Australia’s Authorised Prescriber Scheme, where MDMA is used for PTSD and psilocybin for treatment‑resistant depression. Optimi also supplies a high‑profile PTSD clinical trial for MAPS Israel and has launched an Ibogaine Initiative to target US markets following a 2026 Executive Order.